scholarly journals Antibody-mediated Immunogenicity against SARS-CoV-2 following priming, boosting and hybrid immunity: insights from 11 months of follow-up of a healthcare worker cohort in Israel, December 2020-October 2021

2021 ◽  
Author(s):  
Michael Edelstein ◽  
Karine Beiruti ◽  
Hila Ben Amram ◽  
Naor Bar Zeev ◽  
Christian Sussan ◽  
...  
Keyword(s):  
Geometric Mean ◽  
Age Groups ◽  
Primary Vaccination ◽  
Optimal Timing ◽  
Infection Status ◽  
Igg Antibody ◽  
Antibody Titres ◽  
Previous Infection ◽  
Mean Concentration

Abstract Background: We determined circulating anti-S SARS-CoV-2 IgG antibody titres in a vaccinated healthcare workers (HCWs) cohort from Northern Israel in the 11 months following primary vaccination according to age, ethnicity, boosting timing and previous infection status. Methods: All consenting HCWs were invited to have their circulating IgG levels measured before vaccination and at 6 subsequent timepoints. All HCWs with suspected COVID-19 were PCR tested. We described trends in circulating IgG geometric mean concentration by age, ethnicity, timing of boosting and previous infection status and compared strata using Kruskall-Wallis tests. Results: Among 985 vaccinated HCWs. IgG titres gradually decreased in all groups over the study duration. Younger or previously infected individuals had higher initial IgG levels (p<0.001 in both cases); differences substantially decreased or disappeared at 7-9 months, before boosting. Pre-infection IgG levels in infected participants were similar to levels measured at the same timepoint in HCWs who remained uninfected (p>0.3). IgG GMC in those boosted 6-7 months after dose 2 was lower compared with those boosted 8-9 months after (1999-vs 2736, p=0.02). Conclusions: Immunity waned 6 months post-priming in all age groups and in previously infected individuals, reversed by boosting. IgG titres decrease among previously infected individuals and the proportion of reinfected individuals in this group, comparable to the proportion of breakthrough infection in previously uninfected individuals suggests individuals with hybrid immunity (infection+vaccination) may also require further doses. Our study also highlights the difficulty in determining protective IgG levels and the need to clarify the optimal timing in 3 dose regimens

scholarly journals Incidence of Infection of Enterovirus 71 and Coxsackieviruses A6 and A16 among Household Contacts of Index Cases in Dong Thap Province, Southern Vietnam

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
C. Q. Hoang ◽  
H. D. Nguyen ◽  
N. X. Ho ◽  
T. H. T. Vu ◽  
T. T. M. Pham ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Geometric Mean ◽  
Age Groups ◽  
Enterovirus 71 ◽  
Foot And Mouth Disease ◽  
Household Contacts ◽  
Significant Difference ◽  
Antibody Titers ◽  
Index Cases

Background. Scarce information exists about immunity to hand, foot, and mouth disease (HFMD) among household contacts of index cases in Vietnam and what that means for reducing ongoing HFMD transmission in the community. Methods. We analyzed neutralizing antibodies (NT) and the incidence of enterovirus (EVs) infection among household contacts of index cases in a province where HFMD remains endemic. Throat swab and 2 mL blood samples from household contacts were collected at enrollment, during and after 2 weeks follow-up. Results. The incidence of EV-A71 infection among household contacts was 40/84 (47.6%, 95% Cl: 36.9-58.3%), compared with 106/336 (31.5%, 95% Cl: 26.6-36.5%) for CV-A6 and 36/107 (33.6%, 95% Cl: 24.7-42.6%) for CV-A16. The incidence of CV-A6 infection was fairly constant across ages; in contrast, CV-A71 and CV-A16 had some variation across ages. At baseline, higher geometric mean titer (GMT) of EV-A71, CV-A6, and CV-A16 antibody titers was found for 25-34-year groups (range 216.3 to 305.0) compared to the other age groups. There was a statistically significant difference in GMT values of CV-A6 and CV-A16 between those who had an infection or did not have infection among households with an index case of these serotypes. Conclusions. Our results indicated that adults were becoming infected with HFMD and could be contributing to the transmission. There is, therefore, a need for considering the household setting as an additional target for intervention programs for HFMD.

scholarly journals Immunoglobulin G Avidities in Infants in Mexico after Primary Immunization with Three Doses of Polyribosylribitol Phosphate-Tetanus Toxoid Haemophilus influenzae Type b Vaccine

2008 ◽  
Vol 15 (6) ◽  
pp. 1024-1027 ◽  
Author(s):  
Patricia Gómez-de-León ◽  
F. Javier Díaz-García ◽  
Alberto Villaseñor-Sierra ◽  
Jorge Segura ◽  
Martha I. Carranza ◽  
...  
Keyword(s):  
Haemophilus Influenzae ◽  
Immunoglobulin G ◽  
Geometric Mean ◽  
Age Groups ◽  
Primary Vaccination ◽  
Haemophilus Influenzae Type ◽  
Primary Immunization ◽  
Type B ◽  
Mexican Children ◽  
Polyribosylribitol Phosphate

ABSTRACT Serum immunoglobulin G concentrations and avidities specific to Haemophilus influenzae type b (Hib) were measured in 208 children living in Guadalajara and Mexico City. Protective concentrations were found in 98.9% and 100.0% of participants, respectively. Geometric mean concentrations differed between both populations and/or among age groups. Mean avidities differed only among the 7- to 12-month-old children. Diphtheria-tetanus-whole-cell pertussis-hepatitis B-Hib primary vaccination seems to induce protection in Mexican children.

scholarly journals Outbreak of human toxoplasmosis in a rural area. A three year serologic follow-up study

1982 ◽  
Vol 77 (1) ◽  
pp. 29-36 ◽  
Author(s):  
Sergio Gomes Coutinho ◽  
Anastácio Morgado ◽  
Marina Wagner ◽  
Renato Lobo ◽  
Frits Sutmoller
Keyword(s):  
Clinical Picture ◽  
Clinical Evidence ◽  
Toxoplasma Infection ◽  
Igg Antibody ◽  
Modes Of Transmission ◽  
Follow Up Study ◽  
Farm Population ◽  
Antibody Titres ◽  
Serologic Evidence

Thirty-six persons living on a farm located in the state of Minas Gerais (Brazil) were studied. Nine of them had the glandular form of toxoplasmosis, between May and August, 1976. These nine cases of toxoplasmosis were confirmed serologically by immunefluorescence-IF-, presenting IgG antibody titres between 1:4096 and 1:32000 and IgM antibody titres between 1:16 and 1:8000. Twelve out of thirty-six persons studied were considered to be "dubious cases". They were defined either by presenting a clinical picture compatible with acquired toxoplasmosis, yet having low serologic titres, or inversely they did not have a clear clinical picture but had serologic evidence of recent Toxoplasma infection. Fifteen out of thirty-six persons studied showed neither serologic nor clinical evidence of recent Toxoplasma infection. The epidemiologic information suggests two possible modes of transmission: a) poorly cooked pork at a barbecue party; b) farm vegetables and soil contaminated with Toxoplasma gondii oocysts (rat-cat cycle). Serologic follow-up nine months later in the human farm population demonstrated still high IgG titres, yet they tended to decline and IgM titres became negative. Three years later most of the IgG titres continued to decline and were almost compatible with the titres obtained in Brazilian population surveys.

scholarly journals Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination Era

2008 ◽  
Vol 15 (11) ◽  
pp. 1694-1698 ◽  
Author(s):  
Caroline L. Trotter ◽  
Ray Borrow ◽  
Jamie Findlow ◽  
Ann Holland ◽  
Sarah Frankland ◽  
...  
Keyword(s):  
Similar Pattern ◽  
Geometric Mean ◽  
Herd Immunity ◽  
Age Groups ◽  
Serum Samples ◽  
The United Kingdom ◽  
Specific Igg ◽  
Catch Up ◽  
Antibody Levels ◽  
Mean Concentration

ABSTRACT The United Kingdom introduced meningococcal serogroup C conjugate (MCC) vaccines in 1999, resulting in substantial declines in serogroup C disease and carriage. Here, we measured the age-specific prevalence of serum bactericidal antibodies (SBA) to Neisseria meningitidis serogroup C and immunoglobulin G (IgG) concentrations to serogroups A, C, W-135, and Y in 2,673 serum samples collected in England between 2000 and 2004. We compared the seroprevalence of SBA titers of ≥8 in the postvaccination era with results from an earlier prevaccination study conducted using the same methods. We found that the percentages of individuals with protective SBA titers were higher in 2000 to 2004 in all of the age groups targeted for MCC vaccination. In the postvaccine era, the prevalence of protective titers was high (75%) in children who had recently been offered routine immunization, but this fell to 36% more than 18 months after scheduled immunization. In the cohorts targeted in the catch-up campaign, the percentage achieving SBA titers of ≥8 was higher in children offered the vaccine at ages 5 to 17 years than in children offered the vaccine at ages 1 to 4 years. The geometric mean concentration (GMC) IgG for serogroup C followed a similar pattern, corresponding to the age at and time since scheduled MCC vaccination. Serogroup-specific IgG GMCs for W-135 and Y were low and showed little variation by age. Serogroup A IgG GMCs were higher, possibly reflecting exposure to cross-reacting antigens. Although the incidence of serogroup C disease remains low due to persisting herd effects, population antibody levels to serogroup C meningococci should be monitored so that potentially susceptible age groups can be identified should herd immunity wane.

scholarly journals Determination of immune response of imported Newcastle disease virus vaccines in broiler chickens

1970 ◽  
Vol 6 (2) ◽  
pp. 139-144
Author(s):  
MS Islam ◽  
AKM Khasruzzaman ◽  
MT Hossain ◽  
MT Islam ◽  
MH Chowdhury ◽  
...  
Keyword(s):  
Immune Response ◽  
Newcastle Disease ◽  
Broiler Chickens ◽  
Geometric Mean ◽  
Primary Vaccination ◽  
Unvaccinated Control ◽  
Antibody Titres ◽  
Newcastle Disease Vaccine ◽  
Group 1

A study was undertaken to determine the immune response of eight different imported live NDV vaccines in broiler chickens in the Department of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh during the period from July to December 2008. A total of 55 broiler chickens (Ross breed) were divided into eleven groups such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11 of which group 1, 3, 5, 7 and 9 were vaccinated primarily with Nobilis® MA5+Clone30, Avipro® ND-IB HB1, Cevac® BIL, Newcastle-Bronchitis Vaccine Fortdodge® and Avipro® ND LaSota vaccine respectively at day 5 of age and secondarily with Nobilis® ND Clone 30, Avipro® ND LaSota, Cevac® New L, Newcastle Disease vaccine Fortdodge® and Avipro® ND LaSota vaccine respectively at day 21 of age by single eye instillation and 2, 4, 6, 8 and 10 were vaccinated with the same vaccines respectively by double eye instillation following the same schedule. Group 11 was kept as unvaccinated control. Sera samples were collected after 10 days of each vaccination and at day 5, 15, 20, 31 of age from nonvaccinated control and subjected to HI test for the determination of antibody titres. It was observed that after primary vaccination the geometric mean (GM) of HI titres of double eye vaccinated groups differed significantly (P

scholarly journals Antibody Levels in Ethiopian Children Five Years after Vaccination with Two Different Doses of Hepatitis B Vaccine: Is There a Need for Booster Vaccine?

1998 ◽  
Vol 12 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Edemariam Tsega ◽  
John Horton ◽  
Erik Nordenfelt ◽  
B-J Hansson ◽  
Belachew Tafesse ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Geometric Mean ◽  
Hepatitis B Vaccine ◽  
Hbv Infection ◽  
B Virus ◽  
Antibody Titres ◽  
Antibody Levels ◽  
Surface Antibody ◽  
Different Doses

It was hypothesized that, following effective initial vaccination, a booster dose of hepatitis B vaccine will not be necessary in areas of hyperendemicity for hepatitis B virus (HBV) infection. A total of 314 Ethiopian children, ranging from two to 14 years old, were alternatively vaccinated with 10 and 20 µg hepatitis B vaccine doses, using the initial, one- and six-month schedule. Five years later, 210 of the vaccinees were retested for anti-HBV surface antibody titres. Both 10 and 20 µg doses of hepatitis B rDNA yeast vaccine were equally immunogenic and protective against HBV infection for at least five years despite marked reduction of mean antibody levels and geometric mean titres, with 11% of the vaccinees showing antibodies below the protective level. For firm further recommendations a longer follow-up period of vaccinees is suggested.

scholarly journals Immune Responses to Vi Capsular Polysaccharide Typhoid Vaccine in Children 2 to 16 Years Old in Karachi, Pakistan, and Kolkata, India

2014 ◽  
Vol 21 (5) ◽  
pp. 661-666 ◽  
Author(s):  
R. Leon Ochiai ◽  
M. Imran Khan ◽  
Sajid B. Soofi ◽  
Dipika Sur ◽  
Suman Kanungo ◽  
...  
Keyword(s):  
Hepatitis A ◽  
Capsular Polysaccharide ◽  
Geometric Mean ◽  
Enzyme Linked Immunosorbent Assay ◽  
Typhoid Vaccine ◽  
Igg Antibody ◽  
Vi Capsular Polysaccharide ◽  
Cluster Randomized ◽  
Antibody Levels

ABSTRACTThe geometric mean concentration (GMC) and the proportion maintaining a protective level (150 enzyme-linked immunosorbent assay (ELISA) units [ELU]/ml) 2 years following a single dose of 25 μg of injectable Vi capsular polysaccharide typhoid vaccine was measured against that of the control hepatitis A vaccine in children 2 to 16 years old in cluster randomized trials in Karachi and Kolkata. The GMC for the Vi group (1,428 ELU/ml) was statistically significantly different from the GMC of the control hepatitis A vaccine group (86 ELU/ml) after 6 weeks. A total of 117 children (95.1%) in the Vi group and 9 (7.5%) in the hepatitis A group showed a 4-fold rise in Vi IgG antibody concentrations at 6 weeks (P< 0.01). Protective antibody levels remained significantly different between the two groups at 2 years (38% in the Vi vaccine groups and 6% in the hepatitis A group [P< 0.01]). A very small proportion of younger children (2 to 5 years old) maintained protective Vi IgG antibody levels at 2 years, a result that was not statistically significantly different compared to that for the hepatitis A group (38.1% versus 10.5%). The GMCs of the Vi IgG antibody after 2 years were 133 ELU/ml for children 2 to <5 years old and 349 ELU/ml for children 5 to 16 years old. In conclusion, Vi capsular polysaccharide typhoid vaccine is immunogenic in children in settings of South Asia where typhoid is highly endemic. The antibody levels in children who received this vaccine remained higher than those in children who received the control vaccine but were significantly reduced at 2 years of follow-up.

scholarly journals Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England

2021 ◽  
Author(s):  
Gayatri Amirthalingam ◽  
Jamie Lopez Bernal ◽  
Nick J Andrews ◽  
Heather Whitaker ◽  
Charlotte Gower ◽  
...  
Keyword(s):  
Real World ◽  
Geometric Mean ◽  
Age Groups ◽  
Vaccine Effectiveness ◽  
Previous Infection ◽  
Rising Incidence ◽  
The Uk

Introduction In January 2021, the UK decided to prioritise the delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval until the second dose up to 12 weeks. Methods Serological responses were compared after BNT162b2 and AZD1222 vaccination with varying intervals in uninfected and previously-infected adults aged 50-89 years. These findings are evaluated against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England. Results We recruited 750 participants aged 50-89 years, including 126 (16.8%) with evidence of previous infection; 421 received BNT162b2 and 329 and AZD1222. For both vaccines, over 95% had seroconverted 35-55 days after dose one, and 100% seroconverted 7+ days after dose 2. Following a 65-84 day interval between two doses, geometric mean titres (GMTs) at 14-34 days were 6-fold higher for BNT162b2 (6703; 95%CI, 5887-7633) than AZD1222 (1093; 806-1483), which in turn were higher than those receiving BNT162b2 19-29 days apart (694; 540 - 893). For both vaccines, VE was higher across all age-groups from 14 days after dose two compared to one dose, but the magnitude varied with interval between doses. Higher two-dose VE was observed with >6 week intervals between BNT162b2 doses compared to the authorised 3-week schedule, including ≥80 year-olds. Conclusion Our findings support the UK approach of prioritising the first dose of COVID-19 vaccines, with evidence of higher protection following extended schedules. Given global vaccine constraints, these results are relevant to policymakers, especially with highly transmissible variants and rising incidence in many countries.

scholarly journals Imunogenost poživitvenega cepljenja proti klopnemu meningoencefalitisu

2016 ◽  
Vol 85 (7-8) ◽  
Author(s):  
Lucija Beškovnik ◽  
Tatjana Frelih ◽  
Tatjana Avšič Županc ◽  
Miša Korva ◽  
Alenka Trop Skaza
Keyword(s):  
Blood Sample ◽  
Enzyme Immunoassay ◽  
Booster Dose ◽  
Geometric Mean ◽  
Primary Vaccination ◽  
Careful Consideration ◽  
Tick Borne Encephalitis ◽  
Before And After ◽  
Mean Concentration

AbstractBackground: Tick-borne encephalitis is endemic in Slovenia, but still less than 10 % of people are regularly vaccinated. The proportion of vaccinated individuals was significantly influenced by obligatory vaccination for all Slovenian military conscripts between 1993 and 2003.Methods: Our study includes 73 men from the Celje region, who were vaccinated with three doses of vaccine against tick-borne meningoencephalitis FSME-Immun® (Baxter), but afterwards they stopped the vaccination for a period of 8 to 16 years. Participating men were serologically tested before and after the first booster dose. We used the enzyme immunoassay Enzygnost®.Results: The result of the analysis was, that with most of the participants the value of titer of antibodies before receiving revaccination was protective (n=67; 91,8 %), while after receiving a booster dose, the protective value was exceeded for all participants who have submitted a second blood sample (n=69; 94,5 %). Geometric mean concentration before the booster dose was 56 U/ml and 314 U/ml after the booster dose.Conclusions: Our study confirmed the long-term protection after primary vaccination with three doses against tick-borne encephalitis with men younger than 50 years, by using enzyme immunoassay. The results support the careful consideration of currently recommended revaccination interval.

Management of Haemophilia in Sweden

1976 ◽  
Vol 35 (03) ◽  
pp. 510-521 ◽  
Author(s):  
Inga Marie Nilsson
Keyword(s):  
Factor Viii ◽  
Total Population ◽  
Age Groups ◽  
Factor Ix ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Haemophilia B ◽  
Human Fraction ◽  
Mild Haemophilia

SummaryThe incidence of living haemophiliacs in Sweden (total population 8.1 millions) is about 1:15,000 males and about 1:30,000 of the entire population. The number of haemophiliacs born in Sweden in 5-year periods between 1931-1975 (June) has remained almost unchanged. The total number of haemophilia families in Sweden is 284 (77% haemophilia A, 23% haemophilia B) with altogether 557 (436 with A and 121 with B) living haemophiliacs. Of the haemophilia A patients 40 % have severe, 18 % moderate, and 42 % mild, haemophilia. The distribution of the haemophilia B patients is about the same. Inhibitors have been demonstrated in 8% of the patients with severe haemophilia A and in 10% of those with severe haemophilia B.There are 2 main Haemophilia Centres (Stockholm, Malmo) to which haemophiliacs from the whole of Sweden are admitted for diagnosis, follow-up and treatment for severe bleedings, joint defects and surgery. Minor bleedings are treated at local hospitals in cooperation with the Haemophilia Centres. The concentrates available for treatment in haemophilia A are human fraction 1-0 (AHF-Kabi), cryoprecipitate, Antihaemophilic Factor (Hyland 4) and Kryobulin (Immuno, Wien). AHF-Kabi is the most commonly used preparation. The concentrates available for treatment in haemophilia B are Preconativ (Kabi) and Prothromplex (Immuno). Sufficient amounts of concentrates are available. In Sweden 3.2 million units of factor VIII and 1.0 million units of factor IX are given per year. Treatment is free of charge.Only 5 patients receive domiciliary treatment, but since 1958 we in Sweden have practised prophylactic treatment of boys (4–18 years old) with severe haemophilia A. At about 5-10 days interval they receive AHF in amounts sufficient to raise the AHF level to 40–50%. This regimen has reduced severe haemophilia to moderate. The joint score is identical with that found in moderate haemophilia in the same age groups. For treatment of patients with haemophilia A and haemophilia B complicated by inhibitors we have used a large dose of antigen (factor VIII or factor IX) combined with cyclophosphamide. In most cases this treatment produced satisfactory haemostasis for 5 to 30 days and prevented the secondary antibody rise.

Sign in / Sign up

Export Citation Format

Share Document